Recently, NRAS/BRAF activation was shown to mediate an epithelial-to-mesenchymal transition (EMT) switch in late-stage melanoma that relies on TWIST1; ZEB1, and E-cadherin loss and results in enhanced invasion. The gene discussed is NRAS; the disease is melanoma.